Annual EBITDA
-$21.30 M
+$200.00 K+0.93%
31 December 2023
Summary:
Theriva Biologics annual earnings before interest, taxes, depreciation & amortization is currently -$21.30 million, with the most recent change of +$200.00 thousand (+0.93%) on 31 December 2023. During the last 3 years, it has fallen by -$11.34 million (-113.84%). TOVX annual EBITDA is now -2789.55% below its all-time high of -$737.00 thousand, reached on 01 December 2010.TOVX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$5.00 M
-$621.00 K-14.17%
01 September 2024
Summary:
Theriva Biologics quarterly earnings before interest, taxes, depreciation & amortization is currently -$5.00 million, with the most recent change of -$621.00 thousand (-14.17%) on 01 September 2024. Over the past year, it has dropped by -$817.00 thousand (-19.52%). TOVX quarterly EBITDA is now -571.67% below its all-time high of $1.06 million, reached on 01 June 2010.TOVX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$20.92 M
-$817.00 K-4.06%
01 September 2024
Summary:
Theriva Biologics TTM earnings before interest, taxes, depreciation & amortization is currently -$20.92 million, with the most recent change of -$817.00 thousand (-4.06%) on 01 September 2024. Over the past year, it has increased by +$1.50 million (+6.67%). TOVX TTM EBITDA is now -6872.00% below its all-time high of -$300.00 thousand, reached on 01 March 1993.TOVX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TOVX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +0.9% | -19.5% | +6.7% |
| 3 y3 years | -113.8% | +4.7% | -47.4% |
| 5 y5 years | -38.1% | -58.7% | -35.6% |
TOVX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -113.8% | +0.9% | -19.5% | +31.4% | -47.4% | +9.8% |
| 5 y | 5 years | -113.8% | +0.9% | -143.1% | +31.4% | -120.3% | +9.8% |
| alltime | all time | -2789.6% | +47.9% | -571.7% | +57.9% | -6872.0% | +51.6% |
Theriva Biologics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$5.00 M(+14.2%) | -$20.92 M(+4.1%) |
| June 2024 | - | -$4.38 M(-18.1%) | -$20.10 M(-6.5%) |
| Mar 2024 | - | -$5.35 M(-13.4%) | -$21.50 M(+1.0%) |
| Dec 2023 | -$21.30 M(-0.9%) | -$6.18 M(+47.6%) | -$21.30 M(-5.0%) |
| Sept 2023 | - | -$4.19 M(-27.7%) | -$22.41 M(-3.3%) |
| June 2023 | - | -$5.79 M(+12.5%) | -$23.19 M(+3.5%) |
| Mar 2023 | - | -$5.15 M(-29.4%) | -$22.41 M(+4.2%) |
| Dec 2022 | -$21.50 M(+51.5%) | -$7.29 M(+47.0%) | -$21.50 M(+10.5%) |
| Sept 2022 | - | -$4.96 M(-0.9%) | -$19.46 M(+9.6%) |
| June 2022 | - | -$5.01 M(+18.3%) | -$17.75 M(+11.5%) |
| Mar 2022 | - | -$4.23 M(-19.4%) | -$15.92 M(+12.2%) |
| Dec 2021 | -$14.19 M(+42.5%) | - | - |
| Dec 2021 | - | -$5.25 M(+61.3%) | -$14.19 M(+28.6%) |
| Sept 2021 | - | -$3.26 M(+2.6%) | -$11.04 M(+12.2%) |
| June 2021 | - | -$3.17 M(+26.8%) | -$9.84 M(+3.6%) |
| Mar 2021 | - | -$2.50 M(+19.2%) | -$9.49 M(-4.7%) |
| Dec 2020 | -$9.96 M(-35.4%) | -$2.10 M(+2.0%) | -$9.96 M(-9.6%) |
| Sept 2020 | - | -$2.06 M(-27.3%) | -$11.01 M(-22.1%) |
| June 2020 | - | -$2.83 M(-4.7%) | -$14.13 M(-5.0%) |
| Mar 2020 | - | -$2.97 M(-5.8%) | -$14.88 M(-3.5%) |
| Dec 2019 | -$15.42 M(-10.8%) | -$3.15 M(-39.2%) | -$15.42 M(-0.3%) |
| Sept 2019 | - | -$5.18 M(+44.8%) | -$15.46 M(+6.4%) |
| June 2019 | - | -$3.58 M(+1.9%) | -$14.54 M(-8.5%) |
| Mar 2019 | - | -$3.51 M(+9.9%) | -$15.89 M(-8.1%) |
| Dec 2018 | -$17.30 M(-33.5%) | -$3.19 M(-24.9%) | -$17.30 M(-12.7%) |
| Sept 2018 | - | -$4.25 M(-13.8%) | -$19.82 M(-7.2%) |
| June 2018 | - | -$4.93 M(+0.3%) | -$21.35 M(-6.5%) |
| Mar 2018 | - | -$4.92 M(-13.9%) | -$22.83 M(-12.2%) |
| Dec 2017 | -$26.01 M(-33.5%) | -$5.71 M(-1.3%) | -$26.00 M(-14.6%) |
| Sept 2017 | - | -$5.79 M(-9.8%) | -$30.45 M(-9.8%) |
| June 2017 | - | -$6.42 M(-20.7%) | -$33.77 M(-7.8%) |
| Mar 2017 | - | -$8.09 M(-20.3%) | -$36.64 M(-6.3%) |
| Dec 2016 | -$39.09 M(-4.4%) | -$10.16 M(+11.6%) | -$39.09 M(-3.0%) |
| Sept 2016 | - | -$9.10 M(-2.0%) | -$40.30 M(-5.9%) |
| June 2016 | - | -$9.29 M(-11.9%) | -$42.83 M(-1.0%) |
| Mar 2016 | - | -$10.54 M(-7.2%) | -$43.25 M(+5.7%) |
| Dec 2015 | -$40.91 M(+99.7%) | -$11.36 M(-2.3%) | -$40.91 M(+11.6%) |
| Sept 2015 | - | -$11.63 M(+19.7%) | -$36.64 M(+22.5%) |
| June 2015 | - | -$9.72 M(+18.5%) | -$29.92 M(+20.4%) |
| Mar 2015 | - | -$8.20 M(+15.6%) | -$24.84 M(+21.3%) |
| Dec 2014 | -$20.48 M(+66.6%) | -$7.09 M(+44.6%) | -$20.48 M(+16.0%) |
| Sept 2014 | - | -$4.91 M(+5.6%) | -$17.65 M(+9.6%) |
| June 2014 | - | -$4.65 M(+21.1%) | -$16.10 M(+15.8%) |
| Mar 2014 | - | -$3.84 M(-10.0%) | -$13.90 M(+13.1%) |
| Dec 2013 | -$12.30 M(-28.7%) | -$4.26 M(+27.1%) | -$12.30 M(-38.2%) |
| Sept 2013 | - | -$3.35 M(+37.0%) | -$19.91 M(+8.3%) |
| June 2013 | - | -$2.45 M(+9.9%) | -$18.38 M(+4.2%) |
| Mar 2013 | - | -$2.23 M(-81.2%) | -$17.63 M(+2.3%) |
| Dec 2012 | -$17.24 M(+201.0%) | -$11.87 M(+551.0%) | -$17.24 M(+113.3%) |
| Sept 2012 | - | -$1.82 M(+7.0%) | -$8.08 M(+13.9%) |
| June 2012 | - | -$1.70 M(-7.1%) | -$7.10 M(+14.9%) |
| Mar 2012 | - | -$1.83 M(-32.6%) | -$6.18 M(+7.9%) |
| Dec 2011 | -$5.73 M(+677.1%) | -$2.72 M(+224.2%) | -$5.73 M(+80.8%) |
| Sept 2011 | - | -$839.00 K(+7.0%) | -$3.17 M(+6.6%) |
| June 2011 | - | -$784.00 K(-43.4%) | -$2.97 M(+163.9%) |
| Mar 2011 | - | -$1.38 M(+765.5%) | -$1.13 M(+51.4%) |
| Dec 2010 | -$737.00 K | -$159.90 K(-75.1%) | -$743.20 K(-52.8%) |
| Sept 2010 | - | -$642.10 K(-160.5%) | -$1.57 M(+6.8%) |
| June 2010 | - | $1.06 M(-205.9%) | -$1.47 M(-55.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2010 | - | -$1.00 M(+1.0%) | -$3.32 M(+0.2%) |
| Dec 2009 | -$3.34 M(-51.7%) | -$991.50 K(+82.9%) | -$3.31 M(+5.4%) |
| Sept 2009 | - | -$542.00 K(-31.0%) | -$3.15 M(-20.8%) |
| June 2009 | - | -$785.90 K(-21.0%) | -$3.97 M(-18.7%) |
| Mar 2009 | - | -$994.90 K(+20.9%) | -$4.88 M(-29.4%) |
| Dec 2008 | -$6.91 M(-30.4%) | -$822.90 K(-39.8%) | -$6.91 M(-25.0%) |
| Sept 2008 | - | -$1.37 M(-19.6%) | -$9.22 M(-7.4%) |
| June 2008 | - | -$1.70 M(-43.8%) | -$9.95 M(-1.0%) |
| Mar 2008 | - | -$3.03 M(-3.2%) | -$10.05 M(+1.1%) |
| Dec 2007 | -$9.94 M(+144.0%) | -$3.13 M(+48.6%) | -$9.94 M(+11.4%) |
| Sept 2007 | - | -$2.10 M(+17.0%) | -$8.92 M(+17.9%) |
| June 2007 | - | -$1.80 M(-38.2%) | -$7.57 M(+16.7%) |
| Mar 2007 | - | -$2.91 M(+38.2%) | -$6.48 M(+58.6%) |
| Dec 2006 | -$4.07 M(+209.3%) | -$2.11 M(+181.2%) | -$4.09 M(+106.4%) |
| Sept 2006 | - | -$749.30 K(+4.6%) | -$1.98 M(+60.8%) |
| June 2006 | - | -$716.20 K(+38.9%) | -$1.23 M(+138.9%) |
| Mar 2006 | - | -$515.50 K(-10.2%) | -$515.50 K(-90.8%) |
| Dec 2005 | -$1.32 M(-83.7%) | - | - |
| Mar 2003 | - | -$574.10 K(-29.0%) | -$5.58 M(-31.1%) |
| Dec 2002 | -$8.09 M(-16.4%) | -$808.50 K(-29.0%) | -$8.09 M(-21.1%) |
| Sept 2002 | - | -$1.14 M(-62.7%) | -$10.26 M(-13.3%) |
| June 2002 | - | -$3.05 M(-1.2%) | -$11.84 M(+6.2%) |
| Mar 2002 | - | -$3.09 M(+3.9%) | -$11.15 M(-40.7%) |
| Dec 2001 | -$9.68 M(+56.7%) | -$2.98 M(+9.5%) | -$18.80 M(+6.7%) |
| Sept 2001 | - | -$2.72 M(+15.1%) | -$17.61 M(+8.1%) |
| June 2001 | - | -$2.36 M(-78.0%) | -$16.29 M(+5.7%) |
| Mar 2001 | - | -$10.74 M(+501.0%) | -$15.42 M(+149.5%) |
| Dec 2000 | -$6.18 M(+14.7%) | -$1.79 M(+27.7%) | -$6.18 M(+5.6%) |
| Sept 2000 | - | -$1.40 M(-5.5%) | -$5.85 M(+0.0%) |
| June 2000 | - | -$1.48 M(-1.6%) | -$5.85 M(+2.7%) |
| Mar 2000 | - | -$1.51 M(+3.3%) | -$5.70 M(+6.2%) |
| Dec 1999 | -$5.39 M(+4.6%) | -$1.46 M(+4.2%) | -$5.36 M(+6.1%) |
| Sept 1999 | - | -$1.40 M(+5.3%) | -$5.05 M(+6.3%) |
| June 1999 | - | -$1.33 M(+13.2%) | -$4.75 M(+15.3%) |
| Mar 1999 | - | -$1.17 M(+2.1%) | -$4.12 M(-18.3%) |
| Dec 1998 | -$5.15 M(-34.8%) | -$1.15 M(+4.5%) | -$5.05 M(+32.9%) |
| Sept 1998 | - | -$1.10 M(+57.1%) | -$3.80 M(-15.6%) |
| June 1998 | - | -$700.00 K(-66.7%) | -$4.50 M(-36.6%) |
| Mar 1998 | - | -$2.10 M(-2200.0%) | -$7.10 M(-6.6%) |
| Dec 1997 | -$7.90 M(+8.2%) | $100.00 K(-105.6%) | -$7.60 M(-24.0%) |
| Sept 1997 | - | -$1.80 M(-45.5%) | -$10.00 M(+2.0%) |
| June 1997 | - | -$3.30 M(+26.9%) | -$9.80 M(+21.0%) |
| Mar 1997 | - | -$2.60 M(+13.0%) | -$8.10 M(+14.1%) |
| Dec 1996 | -$7.30 M(0.0%) | -$2.30 M(+43.8%) | -$7.10 M(+6.0%) |
| Sept 1996 | - | -$1.60 M(0.0%) | -$6.70 M(-5.6%) |
| June 1996 | - | -$1.60 M(0.0%) | -$7.10 M(+31.5%) |
| Mar 1996 | - | -$1.60 M(-15.8%) | -$5.40 M(+45.9%) |
| Dec 1995 | -$7.30 M(+15.9%) | -$1.90 M(-5.0%) | -$3.70 M(-54.9%) |
| Sept 1995 | - | -$2.00 M(-2100.0%) | -$8.20 M(+34.4%) |
| June 1995 | - | $100.00 K(0.0%) | -$6.10 M(0.0%) |
| Mar 1995 | - | $100.00 K(-101.6%) | -$6.10 M(-6.2%) |
| Dec 1994 | -$6.30 M(+75.0%) | -$6.40 M(-6500.0%) | -$6.50 M(+400.0%) |
| Sept 1994 | - | $100.00 K(0.0%) | -$1.30 M(-53.6%) |
| June 1994 | - | $100.00 K(-133.3%) | -$2.80 M(-15.2%) |
| Mar 1994 | - | -$300.00 K(-75.0%) | -$3.30 M(0.0%) |
| Dec 1993 | -$3.60 M | -$1.20 M(-14.3%) | -$3.30 M(+57.1%) |
| Sept 1993 | - | -$1.40 M(+250.0%) | -$2.10 M(+200.0%) |
| June 1993 | - | -$400.00 K(+33.3%) | -$700.00 K(+133.3%) |
| Mar 1993 | - | -$300.00 K | -$300.00 K |
FAQ
- What is Theriva Biologics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Theriva Biologics?
- What is Theriva Biologics annual EBITDA year-on-year change?
- What is Theriva Biologics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Theriva Biologics?
- What is Theriva Biologics quarterly EBITDA year-on-year change?
- What is Theriva Biologics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Theriva Biologics?
- What is Theriva Biologics TTM EBITDA year-on-year change?
What is Theriva Biologics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of TOVX is -$21.30 M
What is the all time high annual EBITDA for Theriva Biologics?
Theriva Biologics all-time high annual earnings before interest, taxes, depreciation & amortization is -$737.00 K
What is Theriva Biologics annual EBITDA year-on-year change?
Over the past year, TOVX annual earnings before interest, taxes, depreciation & amortization has changed by +$200.00 K (+0.93%)
What is Theriva Biologics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of TOVX is -$5.00 M
What is the all time high quarterly EBITDA for Theriva Biologics?
Theriva Biologics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $1.06 M
What is Theriva Biologics quarterly EBITDA year-on-year change?
Over the past year, TOVX quarterly earnings before interest, taxes, depreciation & amortization has changed by -$817.00 K (-19.52%)
What is Theriva Biologics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of TOVX is -$20.92 M
What is the all time high TTM EBITDA for Theriva Biologics?
Theriva Biologics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$300.00 K
What is Theriva Biologics TTM EBITDA year-on-year change?
Over the past year, TOVX TTM earnings before interest, taxes, depreciation & amortization has changed by +$1.50 M (+6.67%)